Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?

Clinical and Vaccine Immunology

Volumn 20, Issue 8, 2013, Pages 1099-1107

  Granoff, Dan M ^a   Ram, Sanjay ^b   Beernink, Peter T ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BINDING PROTEIN; COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; BINDING SITE; DRUG FEVER; DRUG PROTEIN BINDING; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; INNATE IMMUNITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT FACTOR H; HUMANS; MENINGOCOCCAL VACCINES; MICE, TRANSGENIC; MUTANT PROTEINS; NEISSERIA MENINGITIDIS; PROTEIN BINDING;

EID: 84880914641     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00260-13     Document Type: Review

References (59)

1. Cohn AC, Macneil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE. 2010. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50:184-191.
2. Harrison LH, Trotter CL, Ramsay ME. 2009. Global epidemiology of meningococcal disease. Vaccine 27:B51-B63.
3. Trotter CL, Ramsay ME. 2007. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol. Rev. 31:101-107.
4. Shepard CW, Rosenstein NE, Fischer M. 2003. Neonatal meningococcal disease in the United States, 1990 to 1999. Pediatr. Infect. Dis. J. 22:418- 422.
5. Baker MG, Martin DR, Kieft CE, Lennon D. 2001. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J. Paediatr. Child Health 37:S13-S19.
6. Rouaud P, Perrocheau A, Taha MK, Sesboue C, Forgues AM, Parent Du Chatelet I, Levy-Bruhl D. 2006. Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro Surveill. 11:178-181.
7. Finne J, Leinonen M, Makela PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
8. Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Hoiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E. 2005. The concept of "tailor-made, " protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23:2202-2205.
9. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl 2):B3-B12.
10. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nokleby H, Rosenqvist E, Solberg LK, Closs O, Froholm LO, Lystad A, Bakketeig LS, Hareide B, Halstensen A, Holten E, Eng J. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338: 1093-1096.
11. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, Zollinger WD. 2011. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, overexpressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29:1413-1420.
12. Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, Granoff DM. 2011. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29:4728- 4734.
13. Koeberling O, Seubert A, Granoff DM. 2008. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J. Infect. Dis. 198:262-270.
14. Granoff DM. 2010. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl 2):S54 -S65.
15. Sadarangani M, Pollard AJ. 2010. Serogroup B meningococcal vaccines- an unfinished story. Lancet Infect. Dis. 10:112-124.
16. Martin D, Cadieux N, Hamel J, Brodeur BR. 1997. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185:1173-1183.
17. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappuoli R. 2000. Identification of vaccine candidates against serogroup B meningococcus by wholegenome sequencing. Science 287:1816-1820.
18. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, Santini L, Biolchi A, Seib KL, Giuliani MM, Donnelly JJ, Berti F, Savino S, Scarselli M, Costantino P, Kroll JS, O'Dwyer C, Qiu J, Plaut AG, Moxon R, Rappuoli R, Pizza M, Arico B. 2010. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc. Natl. Acad. Sci. U. S. A. 107:3770-3775.
19. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. 2003. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. 188:1730-1740.
20. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Arico B, Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, Granoff DM, Caugant DA, Pizza M, Rappuoli R, Mora M. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195:1445-1454.
21. Humphries HE, Williams JN, Blackstone R, Jolley KA, Yuen HM, Christodoulides M, Heckels JE. 2006. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce crossprotective bactericidal immune responses against Neisseria meningitidis. Vaccine 24:36-44.
22. West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M, Robinson A, Gorringe A. 2001. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect. Immun. 69:1561-1567.
23. Carmenate T, Mesa C, Menendez T, Falcon V, Musacchio A. 2001. Recombinant Opc protein from Neisseria meningitidis reconstituted into liposomes elicits opsonic antibodies following immunization. Biotechnol. Appl. Biochem. 34:63-69.
24. Jolley KA, Appleby L, Wright JC, Christodoulides M, Heckels JE. 2001. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect. Immun. 69:3809-3816.
25. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799.
26. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, Xie X, Zagursky R, Zhang Y, Zlotnick GW. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100.
27. Granoff DM. 2013. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease. Pediatr. Infect. Dis. J. 32:372-373.
28. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, Von Gottberg A, Du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379-389.
29. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM. 2011. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin. Vaccine Immunol. 18:1002-1014.
30. Madico G, Welsch JA, Lewis LA, Mcnaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501- 510.
31. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, Tang CM. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566-7575.
32. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, Oster P, Miller E, Pollard AJ. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137.
33. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29:e71- e79.
34. Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, Perez JL. 2012. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr. Infect. Dis. J. 31:1061-1068.
35. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garces- Sanchez M, Martinon-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL. 2012. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 12:597-607.
36. Vu DM, Wong TT, Granoff DM. 2011. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 29:1968-1973.
37. Borrow R, Andrews N, Goldblatt D, Miller E. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:1568- 1573.
38. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor Hbinding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061.
39. Giuntini S, Reason DC, Granoff DM. 2012. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factorH binding proteinInfect. Immun. 80:187-194.
40. Konar M, Granoff DM, Beernink PT. 28 May 2013. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J. Infect. Dis. doi:10.1093/infdis.jit239.
41. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764-769.
42. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. 2008. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect. Immun. 76:4232-4240.
43. Giuntini S, Beernink PT, Reason DC, Granoff DM. 2012. Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. PLoS One 7:e34272. doi:10 .1371/journal.pone.0034272.
44. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, Quoraishi S, Lovett JE, Deane JE, Sim RB, Roversi P, Johnson S, Tang CM, Lea SM. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893.
45. Meri S, Jordens M, Jarva H. 2008. Microbial complement inhibitors as vaccines. Vaccine 26(Suppl 8):I113-I117.
46. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM. 2012. The effect of human factorHon immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog. 8:e1002688. doi:10.1371/journal.ppat .1002688.
47. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186:3606-3614.
48. Johnson S, Tan L, Van Der Veen S, Caesar J, Goicoechea De Jorge E, Harding RJ, Bai X, Exley RM, Ward PN, Ruivo N, Trivedi K, Cumber E, Jones R, Newham L, Staunton D, Ufret-Vincenty R, Borrow R, Pickering MC, Lea SM, Tang CM. 2012. Design and evaluation of me-ningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog. 8:e1002981. doi:10.1371/journal.ppat .1002981.
49. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839.
50. Pajon R, Beernink PT, Granoff DM. 2012. Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect. Immun. 80:2667-2677.
51. Hakobyan S, Harris CL, Tortajada A, Goicochea De Jorge E, Garcia- Layana A, Fernandez-Robredo P, Rodriguez De Cordoba S, Morgan BP. 2008. Measurement of factor H variants in plasma using variantspecific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 49:1983-1990.
52. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, Loveless S, Robertson NP, Morgan BP. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133:1602-1611.
53. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM. 2009. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest. Ophthalmol. Vis. Sci. 50:5818-5827.
54. Heger A, Kannicht C, Romisch J, Svae TE. 2007. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang. 92:206-212.
55. Ufret-Vincenty RL, Aredo B, Liu X, Mcmahon A, Chen PW, Sun H, Niederkorn JY, Kedzierski W. 2010. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. Invest. Ophthalmol. Vis. Sci. 51:5878-5887.
56. Dunphy KY, Beernink PT, Brogioni B, Granoff DM. 2011. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect. Immun. 79:353- 359.
57. Seib KL, Serruto D, Oriente F, Delany I, Adu-Bobie J, Veggi D, Arico B, Rappuoli R, Pizza M. 2009. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect. Immun. 77:292-299.
58. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ. 2012. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307:573- 582.
59. Cohn AC, Messonnier NE. 2012. Inching toward a serogroup B meningococcal vaccine for infants. JAMA 307:614-615.